Profile data is unavailable for this security.
About the company
Day One Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. It partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor. OJEMDA is used for the treatment of patients over six months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. Its pipeline product candidates include DAY301 and Emi-Le (emiltatug ledadotin). DAY301 is a novel Antibody Drug Conjugate, or ADC, targeting protein-tyrosine kinase 7, or PTK7. Emi-Le (emiltatug ledadotin) is a novel antibody drug conjugate (ADC) targeting the B7-H4 protein in clinical development to treat the rare cancer adenoid cystic carcinoma (ACC).
- Revenue in USD (TTM)133.67m
- Net income in USD-151.76m
- Incorporated2018
- Employees184.00
- LocationDay One Biopharmaceuticals Inc1800 Sierra Point Parkway, Suite 200BRISBANE 94005United StatesUSA
- Phone+1 (650) 484-0899
- Fax+1 (302) 636-5454
- Websitehttps://dayonebio.com/
More ▼
Mergers & acquisitions
| Acquired company | DAWN:NSQ since announced | Transaction value |
|---|---|---|
| Mersana Therapeutics Inc | 10.35% | 282.14m |
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rigel Pharmaceuticals Inc | 282.08m | 113.30m | 602.99m | 162.00 | 5.39 | 5.12 | 5.21 | 2.14 | 6.17 | 6.17 | 15.36 | 6.48 | 1.48 | 2.15 | 7.37 | 1,741,210.00 | 59.33 | -16.62 | 97.15 | -28.36 | 93.10 | 95.63 | 40.17 | -16.88 | 2.14 | 25.77 | 0.3368 | -- | 53.38 | 24.77 | 169.69 | -- | -22.92 | -- |
| Sinovac Biotech Ltd | 429.20m | -130.73m | 639.90m | 3.04k | -- | -- | -- | 1.49 | -1.31 | -1.31 | 4.31 | 86.81 | 0.0322 | 0.2019 | 1.08 | 141,325.00 | -2.23 | 36.14 | -3.30 | 58.37 | 92.09 | 90.77 | -69.19 | 65.87 | 11.24 | -- | 0.0262 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
| ASP Isotopes Inc | 8.38m | -105.56m | 652.45m | 136.00 | -- | 6.57 | -- | 77.83 | -1.43 | -1.43 | 0.1124 | 0.7932 | 0.0541 | 8.86 | 0.884 | 61,642.43 | -68.21 | -- | -85.13 | -- | 23.00 | -- | -1,261.23 | -- | 6.10 | -0.6787 | 0.5382 | -- | 857.03 | -- | -115.60 | -- | -- | -- |
| Ironwood Pharmaceuticals, Inc. | 338.99m | 28.55m | 723.92m | 253.00 | 31.69 | -- | 23.77 | 2.14 | 0.1404 | 0.1404 | 2.00 | -1.62 | 0.863 | -- | 3.45 | 1,339,870.00 | 7.27 | -6.08 | 11.57 | -7.13 | -- | -- | 8.42 | -11.01 | -- | 4.73 | 1.82 | -- | -20.63 | -3.89 | 100.09 | -56.87 | -54.38 | -- |
| Esperion Therapeutics Inc | 303.80m | -105.83m | 760.22m | 304.00 | -- | -- | -- | 2.50 | -0.5358 | -0.5358 | 1.54 | -2.20 | 0.896 | 1.35 | 3.25 | 999,348.70 | -31.21 | -61.82 | -138.14 | -101.31 | 58.20 | 81.27 | -34.84 | -109.30 | 0.7017 | -0.3928 | 4.08 | -- | 185.66 | 17.50 | 75.27 | -- | -19.76 | -- |
| Pacira Biosciences Inc | 716.79m | 21.44m | 836.80m | 790.00 | 43.65 | 1.20 | 7.45 | 1.17 | 0.4664 | 0.4664 | 15.70 | 16.93 | 0.5085 | 1.11 | 6.64 | 907,330.40 | 1.52 | 1.87 | 1.78 | 2.22 | 79.17 | 73.06 | 2.99 | 4.84 | 3.78 | -- | 0.3413 | 0.00 | 3.85 | 10.73 | -337.30 | -- | 0.9219 | -- |
| Phathom Pharmaceuticals Inc | 147.19m | -274.55m | 966.96m | 427.00 | -- | -- | -- | 6.57 | -3.81 | -3.81 | 2.04 | -5.95 | 0.4693 | 5.58 | 3.83 | 344,707.30 | -87.53 | -72.89 | -117.10 | -84.11 | 87.25 | -- | -186.53 | -1,799.61 | 2.19 | -3.35 | 3.68 | -- | 8,001.47 | -- | -65.84 | -- | 0.4505 | -- |
| Theravance Biopharma Inc | 80.33m | 29.34m | 992.17m | 97.00 | 34.80 | 4.26 | 32.01 | 12.35 | 0.5626 | 0.5626 | 1.59 | 4.59 | 0.2082 | -- | 4.58 | 828,113.40 | 7.61 | -34.51 | 8.26 | -40.08 | -- | -- | 36.53 | -254.51 | -- | -- | 0.1216 | -- | 12.12 | -2.59 | -2.22 | -- | -36.34 | -- |
| EyePoint Inc | 42.34m | -205.75m | 1.05bn | 165.00 | -- | 4.42 | -- | 24.89 | -2.99 | -2.99 | 0.617 | 2.88 | 0.1532 | 1.02 | 59.51 | 256,606.10 | -74.47 | -35.88 | -86.87 | -42.05 | 94.08 | 84.82 | -485.95 | -201.78 | 7.11 | -- | 0.00 | -- | -5.97 | 16.27 | -84.86 | -- | 80.24 | -- |
| Day One Biopharmaceuticals Inc | 133.67m | -151.76m | 1.08bn | 184.00 | -- | 2.39 | -- | 8.05 | -1.48 | -1.48 | 1.30 | 4.39 | 0.2399 | 2.88 | 10.53 | 738,519.30 | -27.23 | -39.78 | -29.80 | -43.02 | 89.44 | -- | -113.53 | -414.14 | 8.55 | -- | 0.00 | -- | -- | -- | 49.45 | -- | -- | -- |
| Xeris Biopharma Holdings Inc | 266.14m | -15.64m | 1.15bn | 394.00 | -- | -- | -- | 4.31 | -0.1033 | -0.1033 | 1.67 | -0.0052 | 0.77 | 0.7301 | 5.61 | 675,474.60 | -4.52 | -31.61 | -6.46 | -42.28 | 84.56 | 79.76 | -5.88 | -77.77 | 1.35 | 0.3853 | 1.00 | -- | 23.89 | 136.89 | 11.92 | -- | -4.75 | -- |
| Amphastar Pharmaceuticals Inc | 723.31m | 111.63m | 1.32bn | 2.03k | 12.69 | 1.71 | 7.86 | 1.82 | 2.26 | 2.26 | 14.69 | 16.76 | 0.4505 | 2.32 | 5.05 | 356,659.30 | 6.95 | 9.84 | 7.84 | 11.71 | 49.36 | 49.55 | 15.43 | 17.15 | 2.21 | 8.96 | 0.4397 | 0.00 | 13.59 | 17.82 | 15.98 | 26.66 | -0.2486 | -- |
| Collegium Pharmaceutical Inc | 757.07m | 58.44m | 1.48bn | 357.00 | 29.26 | 5.40 | 5.21 | 1.96 | 1.60 | 1.60 | 19.94 | 8.70 | 0.467 | 8.51 | 3.27 | 2,120,636.00 | 3.60 | 4.11 | 5.02 | 6.64 | 57.22 | 55.50 | 7.72 | 8.48 | 1.27 | 2.23 | 0.7462 | 0.00 | 11.41 | 16.31 | 43.68 | -- | -23.82 | -- |
| Precigen Inc | 6.31m | -425.87m | 1.50bn | 143.00 | -- | 35.83 | -- | 237.79 | -1.40 | -1.40 | 0.0212 | 0.1183 | 0.0495 | -- | 11.92 | 44,118.88 | -193.82 | -38.49 | -245.09 | -47.33 | 30.32 | 49.53 | -3,912.92 | -334.29 | 3.95 | -- | 0.6893 | -- | -36.95 | -46.64 | -31.63 | -- | -25.69 | -- |
Data as of Feb 06 2026. Currency figures normalised to Day One Biopharmaceuticals Inc's reporting currency: US Dollar USD
39.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 7.60m | 7.40% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 6.43m | 6.26% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 5.72m | 5.57% |
| Franklin Advisers, Inc.as of 30 Sep 2025 | 3.48m | 3.39% |
| Rubric Capital Management LPas of 30 Sep 2025 | 3.38m | 3.29% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 3.24m | 3.16% |
| Pictet Asset Management SAas of 31 Dec 2025 | 2.99m | 2.91% |
| Vestal Point Capital LPas of 30 Sep 2025 | 2.68m | 2.61% |
| FIAM LLCas of 30 Sep 2025 | 2.49m | 2.42% |
| Alyeska Investment Group LPas of 30 Sep 2025 | 2.21m | 2.16% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
